GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » YoY EPS Growth

Alpha Cognition (Alpha Cognition) YoY EPS Growth : -50.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Alpha Cognition's YoY EPS Growth for the quarter that ended in Mar. 2024 was -50.00%.

Alpha Cognition's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.03.

Alpha Cognition YoY EPS Growth Historical Data

The historical data trend for Alpha Cognition's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition YoY EPS Growth Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
- -230.36 51.35 16.67

Alpha Cognition Quarterly Data
Jan20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.00 40.00 25.00 -20.00 -50.00

Alpha Cognition YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Alpha Cognition's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.15--0.18)/ | -0.18 |
=16.67 %

Alpha Cognition's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.03--0.02)/ | -0.02 |
=-50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Cognition YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (Alpha Cognition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » YoY EPS Growth
Comparable Companies
TSXV:TTI TSXV:COV TSX:TH TSX:APS TSXV:CZO XCNQ:GLAB TSXV:IBT TSX:ATE TSXV:GSD XCNQ:DOSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ACOG:Canada
Address
301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2
Website
https://www.alphacognition.com
Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.